David A. Siegel Allovir, Inc. Transaction History
Two Sigma Advisers, LP
- $41.3 Billion
- Q3 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Allovir, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 508,300 shares of ALVR stock, worth $233,818. This represents 0.0% of its overall portfolio holdings.
Number of Shares
508,300
Previous 634,000
19.83%
Holding current value
$233,818
Previous $456,000
9.87%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding ALVR
# of Institutions
63Shares Held
44.6MCall Options Held
14.9KPut Options Held
200-
Eco R1 Capital, LLC San Francisco, CA11.3MShares$5.2 Million0.4% of portfolio
-
Octagon Capital Advisors LP New York, NY11.2MShares$5.15 Million2.19% of portfolio
-
Siren, L.L.C. New York, NY6.6MShares$3.03 Million0.27% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.28MShares$1.51 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.65MShares$1.22 Million0.0% of portfolio
About Allovir, Inc.
- Ticker ALVR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 93,063,400
- Market Cap $42.8M
- Description
- Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, ...